You are here

INVOKAMET® XR and INVOKAMET® (canagliflozin/metformin HCl) address multiple defects in type 2 diabetes1,2

Kidneys


INVOKAMET® mechanism of action

 

INVOKANA® removes glucose by:
  • Decreasing the renal reabsorption of filtered glucose, increasing urinary glucose excretion

Liver


INVOKAMET® mechanism of action

 

Metformin decreases hepatic glucose production

Intestine


INVOKAMET® mechanism of action

 

Metformin decreases intestinal glucose absorption and INVOKANA® 300 mg reduced postprandial glucose excursion due to delayed glucose absorption
  • In single-dose pharmacokinetic/ pharmacodynamic studies in healthy people and in patients with type 2 diabetes

Peripheral tissue


INVOKAMET® mechanism of action

 

Metformin improves insulin sensitivity by increasing peripheral glucose uptake and utilization

INVOKANA® MOA

Learn about RESOURCES

References: 1. INVOKAMET® XR [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. INVOKAMET® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.